Karyopharm Therapeutics KPTI
NASDAQ KPTI
$0.02 -0.02 (-56.50%)
At close: Nov 10, 2026 · 4:00 PM EST

Karyopharm Therapeutics (KPTI) Net Long-Term Debt Issued (Repaid) (2025)

Updated

Karyopharm Therapeutics (KPTI) posted Non-Current Debt of $85.05 million for Q2 2026, down 5.0% from $89.57 million a year earlier.

Analysis

Karyopharm Therapeutics (KPTI) Net Long-Term Debt Issued (Repaid) (2025) Analysis & Trends

At the end of FY2025, Karyopharm Therapeutics' Non-Current Debt came in at $94.8 million, up 0.2% from FY2024.

  • In prior years, Karyopharm Therapeutics' Non-Current Debt was $94.6 million in FY2024.
  • Quarterly Non-Current Debt has run from a low of $83.9 million in Q3 2025 to a high of $95.2 million in Q1 2025 over five years.
  • On a year-over-year basis, Non-Current Debt increased in 1 of the last four quarters, with an average decline of 5.0%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net LT Debt (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -1.00 Mn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 9.98 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -3.05 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -19.00 Mn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Karyopharm Therapeutics 766,856.99 -264.81 Mn 32.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 27.25 Mn
API Access

Karyopharm Therapeutics Net Long-Term Debt Issued (Repaid) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=KPTI&period=max&api_key=YOUR_API_KEY